Evonik achieves its expected goal: Adjusted interest-tax depreciation and amortization profit is 2.36 billion euros, reaching the expected high level
2018 Expected: Sales The amount and profit double growth, adjusted EBITDA will be between 2.4 billion to 2.6 billion euros
Actively manage the product portfolio: The board of directors is studying the strategic direction of the methacrylate business
Evonik Industries announced its 2017 results and achieved the same results as expected in the past year. The key driver of sales growth in 2017 is organic growth as well as the integration of the previously acquired Air Products Specialty Additives business and the Huber Silicones business Bring the benefits.
For the full year of 2017, sales were 14.4 billion euros, which was a 13% increase from 2016 and 2016 sales of 12.7 billion euros.
EBITDA (before interest, tax, depreciation and amortization) adjusted to 2.36 billion euros in 2017, which is 9% higher than 2016, and 2.165 billion euros in the same period of 2016, and 24.6 billion euros in 2018.
The adjusted net income in 2017 was 1.01 billion euros, which was 9% higher than 2016, and was adjusted to 930 million euros in the same period of 2016.
Dividends per share were 1.15 euros, with a dividend yield of 3.7%.
In 2018, Evonik aims to achieve double growth in sales and operating income. Evonik has a strong market position in the fields of specialty additives, animal nutrition, smart materials, health and nursing, and focuses on these four major growth engines. Chuang is expected to maintain a high level of market demand, and will bring significant sales growth. Evonik has made a good start in the new year.
Actively manage product portfolio
Evonik systematically implements its established strategy, which includes actively managing its product portfolio to focus more on specialty chemicals business. Currently, the Board is studying the business of methacrylates (methacrylate monomer MMA and polymethylmethacrylate Ester PMMA) the future direction of development, including potential cooperation or complete divestiture of the business.
Christian Kullmann, Chairman of Evonik
Christian Kullmann, Chairman of Evonik, said: "Our MMA and PMMA businesses have a leading competitive advantage with attractive and profitable levels, so we can evaluate options without any time pressure to determine the best Program. '
In the nutrition and consumer chemicals business segment, Evonik is gradually strengthening the feed additive business and strengthening its growth initiatives in the field of sustainable animal nutrition to consolidate market leadership. At the same time, by the end of 2020, optimize production, logistics, Sales and marketing will save about 50 million euros.
Continue to optimize administrative and sales processes
In the fall of 2017, Evonik announced that it will optimize its administrative and sales processes to achieve a cost savings of 200 million euros per year by the end of 2020. This represents approximately 10% of global sales and administrative expenses. The cost savings of 50 million euros will be reached this year. The gains are reflected.
'Cost control is an important success factor and is gradually becoming part of our corporate culture.' "Kullmann said." Sales and administrative expenses should not grow faster than sales, so we are moving in a socially acceptable way, Acting globally. '
Sales of all three business segments are growing
Resource Efficiency Business Segment: The business of the segment has achieved great success thanks to higher sales and selling prices and the successful integration of the acquired businesses, especially the silica used in the tire industry for environmentally friendly coatings and Demand for cross-linkers for composites is strong and the business of high-performance polymers (polyamide 12) for the automotive industry is promising, with positive impact.
Nutrition and Consumer Products Chemicals Business Segment: In the second half of the year, with more favorable market conditions, the sector raised the price of feed additives. However, the average price of the market was still far below last year's impact, and the annual revenue dropped sharply. Construction and automotive industry The strong demand for polyurethane foam additives is encouraging. In the medical health business area, polymers for smart drug delivery systems have been very successful.
Functional Materials Business Segment: Revenue from this segment was significantly higher than last year. Demand from the coatings and automotive industries continued to boom, but market supply was tight, especially for methacrylate products. Successful implementation of efficiency measures helped achieve good performance throughout the year.
Board of Supervisors elects Werner Mueller as Honorary Chairman
Evonik Board of Supervisors unanimously elected Dr Werner Mueller as Honorary Chairman at the meeting held on March 5. The Board of Supervisors accepted the proposal of Evonik to implement the Board of Trustees and this vote explicitly endorsed Mueller's outstanding contribution to the company Mueller has been Announced last week that he will resign as chairman of the board of supervisors at the conclusion of the May 23 annual shareholders' meeting.